# SanegeneBio funding rounds and investors

As of 14 Oct 2026, SanegeneBio has raised $110M across 1 verified round on record; latest: $110 million Series B, announced 8 Dec 2025.

Innovative RNAi therapeutics for chronic diseases, targeting autoimmune, cardiovascular, obesity, and metabolic diseases for healthcare providers and researchers.

Website: https://sanegenebio.com  
Page: https://fireround.dev/companies/sanegenebio.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-12-08 | Series B | $110 million | not stated | China Biologic Products Group, Eli Lilly, Invus, Lake Bleu Capital, Legend Holdings, Suzhou Venture Capital, SymBiosis, Vivo Capital, Zhenmai Investment | [vcbeathealth.com](https://www.vcbeathealth.com/article/5362) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.